# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $57 ...
JP Morgan analyst Robbie Marcus maintains AtriCure (NASDAQ:ATRC) with a Overweight and lowers the price target from $42 to $34.
Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $46 to $40.
AtriCure (NASDAQ:ATRC) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.23) by...
Oppenheimer analyst Suraj Kalia upgrades AtriCure (NASDAQ:ATRC) from Perform to Outperform and announces $32 price target.